What’s Next After 20 Years Of NICE?

NICE's Growing Importance Has Brought Increasing Scrutiny

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Brain_Research
With Success Comes Scrutiny • Source: Shutterstock

This year, the National Institute for Health and Care Excellence (NICE), the world-renowned organization that conducts health technology appraisals for England, celebrated its 20th anniversary. Meindert Boysen, who heads NICE’s Center For Health Technology Evaluation, spoke to In Vivo about the ups and downs of the past 20 years and how the institute is preparing for a future with an increasing number of highly priced individualized treatments.

That NICE still exists 20 years on is no small feat, said Boysen. Indeed, he lists this among the institute’s...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Leadership

Vigya test infogram - Clone

add a desc test

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Vigya test infogram

add a desc test

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.